Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBP 398

Next Previous
Drug Profile

BBP 398

Alternative Names: BBP-398; BMS-986466; IACS-15509; SHP2 inhibitor - Navire Pharma

Latest Information Update: 28 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer BridgeBio Pharma; Bristol-Myers Squibb; LianBio; Navire
  • Class Antineoplastics; Indoles; Pyrazines; Small molecules
  • Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 28 Dec 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO)
  • 28 Nov 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease) in China (PO, Capsule)
  • 28 Nov 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in China (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top